Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Applied Genetic Technologies logo

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

Advanced Chart

Key Stats

Today's Range
$0.39
$0.39
50-Day Range
$0.37
$0.42
52-Week Range
$0.23
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

This robot is coming to 65 million Americans … this year.
Robots are the hottest thing going in tech right now. And they just had a coming-out party in Las Vegas. Everywhere you turned at the Consumer Electronics Show, a robot was there to greet you.
Genetic Technologies Limited (GENE)
See More Headlines

AGTC Stock Analysis - Frequently Asked Questions

Applied Genetic Technologies Co. (NASDAQ:AGTC) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/09/2021
Today
5/10/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,940,000.00
Pretax Margin
-21,537.54%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
1.51

Miscellaneous

Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:AGTC) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners